鴻博股份(002229.SZ)擬向深圳中泰達投資 共同開拓手機等5G產業鏈
格隆匯2月28日丨鴻博股份(002229.SZ)公佈,為在手機等5G產業鏈拓展業務,公司於2020年02月27日與深圳市中泰達精密技術有限公司(“深圳中泰達”)簽署意向協議,擬向深圳中泰達投資,共同開拓手機等5G產業鏈。
公司擬以增資入股的方式向深圳中泰達投資不超過人民幣5000萬元,投資後公司在深圳中泰達的股權佔比不超過25%。
標的公司深圳中泰達是註冊於深圳市的有限責任公司,主要業務為塑膠、電子、模具、五金產品的研發、生產與銷售。經過多年的技術積累,深圳中泰達已經具備強大的生產、供貨能力,在手機、平板等結構件加工業務領域具備較強的市場競爭力和盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.